NASDAQ · SLGL
Healthcare · Biotechnology
$68.19
Down-$0.01 (-0.01%)
Updated Oct 28, 2026, 9:38 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SLGL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 27, 2026
SLGL closed at $68.19 after 21 trading sessions, down 5.62% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 27, 2026 | $72.00 | $72.00 | $68.05 | $68.19 | 38.79K |
| Oct 26, 2026 | $70.89 | $71.50 | $68.30 | $69.63 | 47.64K |
| Oct 23, 2026 | $67.37 | $70.63 | $67.125 | $69.45 | 57.77K |
| Oct 22, 2026 | $65.69 | $67.395 | $63.53 | $67.39 | 46.23K |
| Oct 21, 2026 | $66.44 | $69.36 | $64.50 | $65.72 | 60.53K |
| Oct 20, 2026 | $63.68 | $66.98 | $63.68 | $65.81 | 45.18K |
| Oct 19, 2026 | $67.39 | $67.39 | $64.06 | $64.98 | 13.89K |
| Oct 16, 2026 | $69.10 | $69.10 | $62.66 | $64.25 | 71.84K |
| Oct 15, 2026 | $70.00 | $70.00 | $67.5075 | $68.70 | 41.24K |
| Oct 14, 2026 | $69.78 | $71.665 | $68.065 | $69.50 | 27.92K |
| Oct 13, 2026 | $72.805 | $72.805 | $68.30 | $68.30 | 33.74K |
| Oct 12, 2026 | $71.77 | $73.11 | $69.50 | $72.40 | 29.05K |
| Oct 9, 2026 | $69.85 | $72.37 | $68.78 | $71.77 | 31.47K |
| Oct 8, 2026 | $70.46 | $70.92 | $66.52 | $70.34 | 40.98K |
| Oct 7, 2026 | $74.97 | $75.065 | $71.28 | $71.945 | 31.33K |
| Oct 6, 2026 | $78.95 | $79.50 | $73.945 | $75.64 | 43.98K |
| Oct 5, 2026 | $71.20 | $79.01 | $71.20 | $78.95 | 29.25K |
| Oct 2, 2026 | $72.88 | $74.35 | $70.84 | $72.00 | 44.37K |
| Oct 1, 2026 | $74.42 | $74.42 | $70.75 | $73.00 | 32.76K |
| Sep 30, 2026 | $73.33 | $77.67 | $72.87 | $74.28 | 39.18K |
| Sep 29, 2026 | $69.96 | $72.785 | $69.20 | $72.25 | 30.68K |
The latest Smart Investors Daily articles mentioning SLGL.
Company
Market Activity
Research & News
SLGL research
Company profile and research snapshot.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 14, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 24, 2026 | Mizuho | Outperform | — |
| Jan 20, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 19, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and maintains $110 price target.
SeekingAlpha · Oct 15, 2026
2026-10-15. The following slide deck was published by Sol-Gel Technologies Ltd.
Yahoo · Oct 15, 2026
Sol-Gel Technologies (NASDAQ:SLGL) outlined its development and commercialization plans for SGT-610, a topical patidegib treatment being studied to reduce new basal cell carcinomas (BCCs) in patients with Gorlin syndrome, a rare inherited disorder associated with recurrent skin cancers and other man
SeekingAlpha · Oct 14, 2026
Sol-Gel Technologies Ltd. (SLGL) Analyst/Investor Day October 14, 2026 12:00 PM EDTCompany ParticipantsMoshe Arkin - CEO & Executive ChairmanOfer...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLGL.
